Zobrazeno 1 - 10
of 301
pro vyhledávání: '"Jonathon B, Cohen"'
Autor:
Nicole Lamanna, Constantine S. Tam, Jennifer A. Woyach, Alvaro J. Alencar, M. Lia Palomba, Pier Luigi Zinzani, Ian W. Flinn, Bita Fakhri, Jonathon B. Cohen, Arrin Kontos, Heiko Konig, Amy S. Ruppert, Anindya Chatterjee, Richard Sizelove, Livia Compte, Donald E. Tsai, Wojciech Jurczak
Publikováno v:
eJHaem, Vol 5, Iss 5, Pp 929-939 (2024)
Abstract Clinical bleeding events are reported here from 773 patients with B‐cell malignancies receiving pirtobrutinib monotherapy from the phase 1/2 BRUIN study (ClinicalTrials.gov identifier: NCT03740529), either in the presence or absence of ant
Externí odkaz:
https://doaj.org/article/82cd9c8755ab4351873ea8a263b45176
Autor:
Nirav N. Shah, Michael Wang, Lindsey E. Roeker, Krish Patel, Jennifer A. Woyach, William G. Wierda, Chaitra S. Ujjani, Toby A. Eyre, Pier Luigi Z inzani, Alvaro J. Alencar, Paolo Ghia, Nicole Lamanna, Marc S. Hoffmann, Manish R. Patel, Ian Flinn, James N. Gerson, Shuo Ma, Catherine C. Coombs, Chan Y. Cheah, Ewa Lech-Maranda, Bita Fakhri, Won Seog Kim, Minal A. Barve, Jonathon B. Cohen, Wojciech Jurczak, Talha Munir, Meghan C. Thompson, Donald E. Tsai, Katherine Bao, Nicholas A. Cangemi, Jennifer F. Kherani, Richard A. Walgren, Hongmei Han, Amy S. Ruppert, Jennifer R. Brown
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation. The phase 1/2 BRUIN study evaluated pirtobrutinib, a highly selective non-covalent (reversible) BT
Externí odkaz:
https://doaj.org/article/14e14931fbe749748bffaa96d517c4bb
Autor:
Narendranath Epperla, Lei Feng, Nirav N. Shah, Lindsey Fitzgerald, Harsh Shah, Deborah M. Stephens, Catherine J. Lee, Thomas Ollila, Geoffrey Shouse, Alexey V. Danilov, Kevin A. David, Pallawi Torka, Hamza Hashmi, Brian Hess, Stefan K. Barta, Jason T. Romancik, Jonathon B. Cohen, Kaitlin Annunzio, Adam S. Kittai, John Reneau, Joanna Zurko, Imran A. Nizamuddin, Jane N. Winter, Leo I. Gordon, Shuo Ma, Romil Patel, Loretta Nastoupil, Sairah Ahmed, Reem Karmali
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-7 (2023)
Abstract Chimeric antigen receptor T-cell therapy (CAR-T) has been successful in treating relapsed/refractory B-cell lymphomas. However, its role in the treatment of diseases involving the central nervous system (CNS) is not well studied. We performe
Externí odkaz:
https://doaj.org/article/c3e2fa17ee934883ab1d81fbb67a6b3b
Autor:
Matthew J. Maurer, Carla Casulo, Melissa C. Larson, Thomas M. Habermann, Izidore S. Lossos, Yucai Wang, Loretta J. Nastoupil, Christopher Strouse, Dai Chihara, Peter Martin, Jonathon B. Cohen, Brad S. Kahl, W Richard Burack, Jean L. Koff, Yong Mun, Anthony Masaquel, Mei Wu, Michael C. Wei, Ashwini Shewade, Jia Li, James R. Cerhan, Brian K. Link, Christopher R. Flowers
Publikováno v:
Haematologica, Vol 999, Iss 1 (2023)
Mosunetuzumab is a novel bispecific antibody targeting epitopes on CD3 on T cells and CD20 on B cells with the goal of inducing T-cell mediated elimination of malignant B cells. A recent pivotal phase I/II clinical trial (GO29781) demonstrated that m
Externí odkaz:
https://doaj.org/article/1d7e46afb331468e9c6f00cad9ff0929
Autor:
Lydia Scarfò, Manish R. Patel, Toby A. Eyre, Wojciech Jurczak, David Lewis, Thomas Gastinne, Shuo MA, Jonathon B. Cohen, Krish Patel, Jennifer R. Brown, Talha Munir, Ewa Lech-Maranda, Marc S. Hoffmann, Chaitra S. Ujjani, Bita Fakhri, Michael Wang, Koji Izutsu, Hirokazu Nagai, Constantine S. Tam, John F. Seymour, Joanna Rhodes, Julie Vose, Matthew Mckinney, James N. Gerson, Minal A. Barve, Bryone Kuss, Youngil Koh, Wei Gao, Amy S. Ruppert, Richard A. Walgren, Donald E. Tsai, Binoj Nair, Katherine Bao, Anthony R. Mato, Chan Y. Cheah, M Lia Palomba
Publikováno v:
HemaSphere, Vol 7, p e852670f (2023)
Externí odkaz:
https://doaj.org/article/a040220921ef4307b9e157dc91a3150b
Autor:
Christopher Dittus, Natalie Grover, Tarsheen Sethi, Jonathon B. Cohen, Alfredo Voloschin, Janhvi Rabadey, Xianming Tan, Anne Beaven, Steven I. Park
Publikováno v:
eJHaem, Vol 3, Iss 3, Pp 734-738 (2022)
Externí odkaz:
https://doaj.org/article/6fdb2b8ac5174e959f92c2353f2afae5
Autor:
Jennifer L. Crombie, Caron A. Jacobson, Robert Redd, Geoffrey Shouse, Alex F. Herrera, Victor A. Chow, Jordan Gauthier, Erin Mullane, Kirk Cahill, Justin Kline, Jason Romancik, Jonathon B. Cohen, Anna Saucier, Roch Houot, Philippe Armand, Brian Hess
Publikováno v:
Haematologica, Vol 108, Iss 12 (2023)
Externí odkaz:
https://doaj.org/article/5acdfcb9d33441d58498adc67547a25c
Autor:
Max J. Gordon, David A. Bond, Adam S. Kittai, Neda Amirmokhtari, Abigail Steinbrunner, Allison Huffman, Victor Orellana-Noia, Geoffrey Shouse, Jonathon B. Cohen, Tycel Phillips, Alexey V. Danilov
Publikováno v:
Haematologica, Vol 108, Iss 11 (2023)
Externí odkaz:
https://doaj.org/article/a3b23f5e184c4c86aebec13ccb58875e
Autor:
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K. Moyo, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Luke Zurbriggen, Cherie Tan, Kathryn Lindsey, Joseph Maakaron, Paolo F. Caimi, Pallawi Torka, Celeste Bello, Sabarish Ayyappan, Reem Karmali, Seo-Hyun Kim, Anna Kress, Shalin Kothari, Yazeed Sawalha, Beth Christian, Kevin A. David, Irl Brian Greenwell, Murali Janakiram, Vaishalee P. Kenkre, Adam J. Olszewski, Jonathon B. Cohen, Neil Palmisiano, Elvira Umyarova, Ryan A. Wilcox, Farrukh T. Awan, Juan Pablo Alderuccio, Stefan K. Barta, Natalie S. Grover, Nilanjan Ghosh, Nancy L. Bartlett, Alex F. Herrera, Geoffrey Shouse
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-6 (2022)
Abstract Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical pra
Externí odkaz:
https://doaj.org/article/742e9377f2884da1b8eeb0b6ff560e57
Autor:
Aditya Rali, Lucy T. Xu, Caroline Craven, Jonathon B. Cohen, Steven Yeh, Hans E. Grossniklaus, Ghazala D. O’Keefe
Publikováno v:
International Journal of Retina and Vitreous, Vol 7, Iss 1, Pp 1-4 (2021)
Abstract Background Intraocular lymphoma accounts for fewer than 1% of intraocular tumors. When the posterior segment is involved, it can be further classified as vitreoretinal or choroidal lymphoma. Vitreoretinal lymphoma (VRL) can rarely masquerade
Externí odkaz:
https://doaj.org/article/547bc54cf7854795a09fd582b3b9e63c